FDA and CMS: A Path for Parallel Approvals for Innovative Technologies
April 1, 2012
Partner Judith Waltz authored an article that appeared in Medical Design on April 1, 2012 titled “FDA and CMS: A path for parallel approvals for innovative technologies.”
Click here to read the complete article.
Click here to read the complete article.
Author(s)
Related Insights
December 5, 2025
Labor & Employment Law Perspectives
Ninth Circuit Ruling Upholds Employee Speech Amid Stalled NLRB
Like it or not, social media has become the backdrop of almost everything we do. It's how many people read the news, interact with…
December 5, 2025
Legal News: International Trade Enforcement & Compliance
What Every Multinational Should Know About … Preserving the Right to IEEPA Tariff Refunds
Any company that has imported goods subject to the Trump administration’s fentanyl-based tariffs or reciprocal tariffs — i.e., the tariffs levied pursuant to the International Emergency Economic Powers Act (the IEEPA tariffs) — needs to consider filing an action in the U.S. Court of International Trade (CIT) to preserve the possibility of recovering refunds of these tariffs.
December 4, 2025
Manufacturing Industry Advisor
Foley Automotive Update
Analysis by Julie Dautermann, Competitive Intelligence Analyst Foley is here to help you through all aspects of rethinking your long-term…